Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

abciximab

REOPRO

abciximab (REOPRO) is a integrin alpha-v/beta-3 inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 8
News articles 0
Drug details — abciximab
US status
approved
Class
—
Route
INJECTION
Patents
20
Programs
8
Data quality
0.84
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

abciximab (REOPRO) is a integrin alpha-v/beta-3 inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN abciximab
Brand REOPRO
Mechanism Integrin alpha-V/beta-3 inhibitor
Target Integrin alpha-IIb/beta-3
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Integrin alpha-V/beta-3 inhibitor

Primary target: Integrin alpha-IIb/beta-3

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline
  1. AUTOP 2 Phase 3 · Ishita Pharma - · Bacterial vaginosis, High risk preterm birth pregnancy, Vagi
  2. Adjuvant Immunomodulatory (IM) Therapy Phase 3 · Ultragenyx UK · Mucopolysaccharidosis IIIA
  3. PRO 2000/5 Phase 3 · United Therapeutics Europe · HIV Infections
  4. 2023/3668 Phase 2 · George Institute for · Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-lo
  5. MSC-NTF cells transplantation (IM) Phase 2 · BRAINSTORM CELL THERAPEUTICS · Amyotrophic Lateral Sclerosis
  6. Pro insulin peptide Phase 2 · Cardiff Oncology · Type 1 Diabetes
  7. PRO 2000/5 Gel (P) Phase 1 · BRIGHT MINDS BIOSCIENCES · HIV Infections
  8. Abciximab local infusion Unknown · Atrium Therapeutics · Acute Anterior Myocardial Infarction

Related & competitor drugs

Browse all drugs
  1. eptifibatide Blood and blood forming organs (B01)
  2. tirofiban hydrochloride Integrin alpha-IIb/beta-3 inhibitor

Related patents

Browse patents

  1. US 12233092

    MSC-NTF specific exosomes and use thereof

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11793912

    Cross-linked fatty acid-based biomaterials

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11166929

    Fatty-acid based particles

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11097035

    Compositions and methods for altering the rate of hydrolysis of cured oil-based materials

    Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11083823

    Tissue-separating fatty acid adhesion barrier

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10869902

    Cured gel and method of making

    Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10814043

    Cross-linked fatty acid-based biomaterials

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10792312

    Barrier layer

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10772995

    Cross-linked fatty acid-based biomaterials

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10603153

    Hernia patch

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10322213

    Compositions and methods for altering the rate of hydrolysis of cured oil-based materials

    Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10285964

    Fatty-acid based particles

    Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10016465

    Cured gel and method of making

    Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9844611

    Tissue-separating fatty acid adhesion barrier

    Expires Mon Dec 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9827352

    Cross-linked fatty acid-based biomaterials

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9827353

    Cross-linked fatty acid-based biomaterials

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9801913

    Barrier layer

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9682175

    Coating material and medical device system including same

    Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9427423

    Fatty-acid based particles

    Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9278161

    Tissue-separating fatty acid adhesion barrier

    Expires Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is abciximab?

abciximab (REOPRO) is a integrin alpha-v/beta-3 inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for abciximab?

REOPRO is a marketed brand name for abciximab. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of abciximab?

abciximab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.